Issues: Vax Specific

Anthrax

Hepatitis B

Hib 

HPV

Influenza

Lyme Disease
Meningococcal

MMR    

Pneumococcal

Polio

Rotavirus

● Smallpox

Tdap/Td

Varicella

Yellow Fever

 

Issues: Misc

Exemptions

Legislation 

New Vax Status

Religion

Thimerosal

 

Vaccine Info

2014 Schedule

ACIP Recs

Components
IOM Reports

● Vax Injury Comp Program
Manufacturer Links

Package Inserts

Reporting AEs

Thimerosal Table

VAERS

VISs

 

Links
 

Search
 

About IVS

Faculty Biographies

Publications

Donations

 

Email IVS

 

Disclaimers & Privacy
 

 
 
 



INFLUENZA VACCINE

Flumist only available in Quadrivalent form.  MedImmune announced that, starting with the 2013/14 season, FluMist will no longer be available in the trivalent fom. MedImmune Press Release 7-26-13

Influenza Vaccines Approved for US
2014-15

Trivalent
click vaccine name to link to insert

Quadrivalent
click vaccine name to link to insert

Manufacturer

Ages

Afluria

 

CSL

5 yrs and older

Agriflu

 

Novartis

18 yrs and older

Fluarix

Fluarix Quadrivalent 

GSK

3 yrs and older

Flublok

 

Protein Sciences Corporation

18 -49 yrs

Flucelvax

 

Novartis

18 yrs and older

FluLaval

 FluLaval Quadrivalent

ID Biomedical

3 yrs and older

Fluvirin 

 

Novartis

4 yrs and older

Fluzone

Fluzone Quadrivalent

sanofi pasteur

6 mos and older

Fluzone High-Dose

 

sanofi pasteur

65 years and older

Intranasal

 

 

 

 

FluMist Quadrivalent

MedImmune

2-49 yrs

Intradermal

 

 

 

Fluzone Intradermal

 

sanofi pasteur

18-64 yrs

CDC's ACIP Recommendations include not recommending Afluria for children younger than 9 years, updated influenza vaccine schedule for everyone 6 months and older, guidance for people with egg allergies and discussion of the newly approved quadrivalent vaccine.  MMWR 2012;61(32):613.. (8/17/12)

FDA approves 2012-13 Influenza Vaccines.  US influenza vaccines for 2012–13 season to contain A/California/7/2009 (H1N1)-like, A/Victoria/361/2011 (H3N2)-like, and B/Wisconsin/1/2010-like (Yamagata lineage) antigens  (8-13-12 FDA News Release)


Narcolepsy and Pandemirix.  WHO safety committee indicates possible association between a novel adjuvanted H1N1 influenza vaccine used in Europe and onset of narcolepsy in children. The Pandemirix vaccine was not used in the United States and at present we are unaware of any associations between any other vaccines and the onset of narcolepsy in adolescents which is a rare genetic disorder.
- GACVS/WHO - Statement on Narcolepsy and vaccination (04-21-11)
- Montastruc JL, Durrieu G, Rascol O. Pandemrix, (H1N1)v influenza and reported cases of narcolepsy. Vaccine 2010;29(11). 

Older Information

All 2009 H1N1 vaccine monovalent vaccine manufactured in 2009 and distributed in the United States expired by September 15, 2010, regardless of the date on the label. link to CDC

The Advisory Committee on Immunization Practices (ACIP) Recommends Influenza Vaccine to everyone older than 6 months of age.  The ACIP recommendation, likely to be accepted by the CDC Director and HHS Secretary, will apply to the 2010/11 flu season. CDC Press Release 2-24-2010

Certain lots of Sanofi Pasteur's H1N1 in pre-filled syringes should be used by February 15, 2010. There are no safety concerns with these lots, the shelf life is just shorter than indicated on the lable. [02-02-10] More information, including lot numbers | CDC Q&A

Nasal Spray H1N1 Vaccine Recalled Due to Decreased Potency.  The 13 lots of MedImmune's vaccine are being recalled due to sub-par potency; not because of safety concerns.  Most doses are believed to have been administered while they were fully potent. [12-12-09]  More info, including lot numbers | CDC Q&A

Non-Safety-Related Recall of Certain Lots of Sanofi Pasteur H1N1 Pediatric (0.25mL, for 6-35 month olds) Vaccine in Pre-Filled Syringes.  Sanofi Pasteur has recalled this vaccine because of decreased potency - not because of safety concerns  - in these lot numbers: UT023DA, UT028DA, UT028CB, UT030CA.  [12-15-09] More info

CDC summary of adverse events following 2009 influenza vaccines reported to VAERS. Enhanced surveillance for vaccine safety is being conducted this year. No unusual adverse events have been identified as causally related to the 2009 H1N1 vaccines. MMWR 12-04-09

The US FDA approved Novatis' seasonal influenza vaccine, Agriflu. This single dose vaccine is for ages 18 and older.  FDA Press Release 11-27-09

Flu Vaccine Monitoring information provided by Uppsala Monitoring Centre (in Sweden). Lists countries using H1N1 vaccine, publishing AEFI reports, etc.  UMC Page

The US FDA approved CSL's influenza vaccines for infants and children.  Both the seasonal and the H1N1 by CSL are now approved for children as young as 6 months.   FDA Press Release 11-12-09

The US FDA approved GlaxoSmithKline's H1N1 vaccine.  With this latest approval, there are now 5 H1N1 vaccines approved  in the US.   FDA Press Release 11-16-09

GlaxoSmithKline's seasonal influenza vaccine, Fluarix, has been approved by the US FDA to include ages 3-17 years.  The prior approved use was adults 18 years and older.  Fluarix is does not protect against H1N1; it is the vaccine for the 2009/20 seasonal flu.  FDA Press Release 10-19-09

Monitoring influenza vaccine safety.  With support from the CDC, we have created an automated internet-based system that will follow-up on any self-reported adverse symptoms to influenza vaccine after vaccination. 
more information about the survey | Washington Post article on this effort

The US FDA approved four H1N1 vaccines.  Three are traditional shots; MedImmune’s is a nasal spray similar to FluMist (the other manufacturers are CSL, Novartis and sanofi Pasteur).  These vaccines are expected to be available to the public in October, some lots may be available earlier.  The people recommended to receive the vaccine first are children 6 months to 4 years, pregnant women, caregivers to infants younger than 6 months, health care/emergency workers who directly deal with patients and kids 5-18 years with chronic medical conditions. more info at WebMD.

"Prepare for a Vaccine Controversy" - on H1N1 flu/vaccine and how the government should explain the risks.  Op-Ed by Arthur Allen in August 1 2009 NYTimes
With the new H1N1 virus continuing to cause illness, hospitalizations and deaths in the US during the normally flu-free summer months and some uncertainty and about what the upcoming flu season might bring, CDC's Advisory Committee on Immunization Practices has taken an important step in preparations for a voluntary novel H1N1 vaccination effort to counter a possibly severe upcoming flu season. On July 29, 2009, ACIP met to consider who should receive novel H1N1 vaccine when it becomes available. more info from CDC

ACIP Recommendations on the Prevention and Control of Seasonal Influenza with Vaccines.  MMWR July 31, 2009. pdf |html

The US FDA approved FluMist, by MedImmune, for use in people 2-49 years of age.  This expansion now includes children 2-5 years of age.  FDA Press Release (9-19-07)

The US FDA approved Glaxo SmithKline's FluLaval influenza virus vaccine. FluLaval is for adults 18 years and older to protect against strains of influenza projected to impact the Northern Hemisphere in the 2006/07 flu season. FluLaval is manufactured by ID Biomedical Corp (a Canadian subsidiary of GlaxoSmithKline) and distributed by GSK. FDA Press Release (10-05-06)

The US FDA announces approval of Fluarix, an inactivated influenza vaccine for adults. Fluarix is manufactured in Germany by a subsidiary of GlaxoSmithKline. FDA Press Release (08-31-05)

CDC's guidelines for controlling influenza transmission in long-term care facilities (11-15-07).  PDF (150k) | HTML version

A new Influenza vaccine will be available for the 2005/6 Flu Season: The FDA has approved the license supplement of sanofi pasteur) to market a formula of their influenza vaccine produced without introducing preservatives at any step in the manufacturing process. Fluzone®, Influenza Virus Vaccine, No Preservative, Pediatric Dose is the only influenza vaccine approved for use in the U.S. in children as young as 6 months. The vaccine will be available in 0.25 mL pediatric dose and 0.50 mL for children 3 years and older. (03-09-05)

The Centers for Disease Control and Prevention has a web page devoted to the Seasonal Flu containing a wide variety of information and updates including the a US map showing flu influenza activity. 

The FDA and CDC address rumors about influenza vaccines (10-17-03). Information from a Press Release.

 

 

This page was last updated on December 13 2013.

© 20134 Institute for Vaccine Safety